HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and maintained a $16 price target.
August 14, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Summit Therapeutics and maintained a $16 price target.
The reiteration of a Buy rating and the maintenance of a $16 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100